Get the Stockscreener App
1.03
6.36%
-0.07
After Hours:
1.08
0.05
+4.85%
Artelo Biosciences Inc stock is traded at $1.03, with a volume of 51,062.
It is down -6.36% in the last 24 hours and down -11.97% over the past month.
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors and neurotransmitters that form a biochemical communication network in body. It is focused on discovering, licensing, developing, and commercializing treatments that control endocannabinoid systems. The company pursues technologies and programs that offer proprietary approaches to cannabinoid-based therapies, also those derived from the cannabis plant and synthetic cannabinoids, as well as new chemical entities and compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare and orphan disease.
See More
Previous Close:
$1.10
Open:
$1.07
24h Volume:
51,062
Relative Volume:
3.12
Market Cap:
$3.55M
Revenue:
-
Net Income/Loss:
$-9.60M
P/E Ratio:
-0.3102
EPS:
-3.32
Net Cash Flow:
$-8.96M
1W Performance:
-10.43%
1M Performance:
-11.97%
6M Performance:
-28.47%
1Y Performance:
-21.97%
1-Day Range:
$1.02
$1.12
1-Week Range:
$1.02
$1.1702
52-Week Range:
$1.00
$1.75
Artelo Biosciences Inc Stock (ARTL) Company Profile
Name
Artelo Biosciences Inc
Sector
Industry
Phone
858-925-7049
Address
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
Compare ARTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
1.03 | 3.55M | 0 | -9.60M | -8.96M | -3.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
464.56 | 119.70B | 10.63B | -479.80M | -1.35B | 13.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.87 | 82.75B | 13.85B | 4.65B | 3.32B | 35.06 |
|
ARGX
Argen X Se Adr
|
614.59 | 36.73B | 1.86B | -40.29M | -1.28B | -4.16 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.74 | 32.53B | 2.09B | -332.26M | 16.06M | -4.14 |
|
BNTX
Biontech Se Adr
|
120.72 | 28.50B | 3.30B | -501.07M | 1.03B | 11.54 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-21 | Initiated | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc Stock (ARTL) Latest News
Artelo Biosciences (ARTL) Stock Surges Amid Strong Buy Ratings - GuruFocus.com
Artelo Biosciences to Present Key Drug Development Data at Major Cannabinoid Summit | ARTL Stock News - StockTitan
HC Wainwright Has Negative Outlook of ARTL FY2024 Earnings - Defense World
HC Wainwright Reiterates “Buy” Rating for Artelo Biosciences (NASDAQ:ARTL) - Defense World
Cancer Anorexia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Helsinn Healthcare, Artelo Biosciences, NGM Biopharmaceuticals - The Globe and Mail
Artelo Biosciences Inc. (ARTL) Quarterly 10-Q Report - Quartz
Artelo Biosciences Reports Q3 2024 Financials and Progress - TipRanks
Artelo Biosciences (ARTL) Stock Dips Amidst Financial Report - GuruFocus.com
Artelo Biosciences Announces Promising New Data on Novel Non-Opioid Treatment Approach for Osteoarthritis Pain at the 13th Annual Musculoskeletal Repair and Regeneration Symposium - The Manila Times
Artelo's Pain Drug Outperforms Naproxen in Key Study; FDA Clears Phase 1 Trial | ARTL Stock News - StockTitan
Tempest Receives FDA Study May Proceed for Pivotal Phase 3 Trial of Amezalpat Combination Therapy for the Treatment of First-Line Hepatocellular Carcinoma - The Manila Times
Artelo Bio Slashes Losses 54%, Advances Pipeline with Multiple Clinical Trials Ahead | ARTL Stock News - StockTitan
Artelo Biosciences (ARTL) Shares Dive Amidst Biotech Sector Move - GuruFocus.com
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting - The Manila Times
Artelo Biosciences Announces Acceptance of ART26.12 into the National Institutes of Health’s “Preclinical Screening Platform for Pain” Program - StockTitan
Artelo Biosciences (ARTL) Stock Surges Amid Bullish Analyst Rati - GuruFocus.com
Artelo Biosciences CEO to Participate in Fireside Chat at the Maxim Group Virtual Healthcare Summit on October 16th - The Manila Times
How doctors hope new cannabis drug will help cancer patients gain weight - inews
FABP5 inhibitor ART-26.12 exhibits activity in psoriasis models - BioWorld Online
Artelo Biosciences shares initiated with Buy by EF Hutton - Investing.com UK
EF Hutton Initiates Coverage of Artelo Biosciences (ARTL) with Buy Recommendation - MSN
Equities Analysts Offer Predictions for Stitch Fix, Inc.’s Q1 2025 Earnings (NASDAQ:SFIX) - Defense World
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Update - Defense World
Anorexia Nervosa Market Expected to Experience Major Growth - openPR
ARTL stock touches 52-week low at $1.12 amid market challenges - Investing.com Canada
Artelo Biosciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
ARTL Stock Earnings: Artelo Biosciences Beats EPS for Q2 2024 - MSN
ARTLW (Artelo Biosciences) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
ARTL (Artelo Biosciences) EV-to-Revenue : (As of Aug. 18, 2024) - GuruFocus.com
ARTL (Artelo Biosciences) EV-to-Revenue : (As of Aug. 17, 2024) - GuruFocus.com
HC Wainwright Weighs in on Artelo Biosciences, Inc.’s Q3 2024 Earnings (NASDAQ:ARTL) - Defense World
Artelo Biosciences’ (ARTL) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Artelo Biosciences (NASDAQ:ARTL) Announces Earnings Results - Defense World
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update - BioSpace
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Up 3,808.3% in July - Defense World
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Down 91.5% in July - Defense World
New drug to control pain related to cancer treatment originally developed at Stony Brook gets FDA clearance - TBR News Media
UK life sciences can lead the way in global cannabinoid R&D says CRDG report - European Pharmaceutical Manufacturer
Artelo’s FABP5 inhibitor cleared to enter clinic for chemotherapy-induced peripheral neuropathy - BioWorld Online
Artelo Biosciences Inc (ARTL)’s Market Momentum: Closing Strong at 1.33, Up 2.71 - The Dwinnex
FDA greenlights Artelo Biosciences' neuropathy drug trial By Investing.com - Investing.com Nigeria
PSEG sets $0.60 quarterly dividend for Q3 2024 By Investing.com - Investing.com
Artelo Biosciences Inc (ARTL) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
FDA clears Artelo’s FABP5 inhibitor trial - Yahoo Finance
Artelo stock jumps 13% after FDA okays ART26.12 Phase 1 study (NASDAQ:ARTL) - Seeking Alpha
Artelo Biosciences Receives FDA Clearance of its IND Application for ART26.12, a Selective Fatty Acid Binding Protein 5 Inhibitor - ForexTV.com
Pharmacokinetic evaluation of novel cannabidiol formulation presented - BioWorld Online
Artelo Biosciences Presents Data From Preclinical Studies On ART12.11 At 34th Annual International Cannabinoid Research Society Symposium - Quantisnow
Artelo Biosciences Presents Comparative Data from Key Preclinical Studies on ART12.11 at the 34th Annual International Cannabinoid Research Society Symposium - Yahoo Finance
Artelo Biosciences Announces Data Supporting Broad Potential Utility of its FABP Inhibitor Platform - StockTitan
Artelo Biosciences Presents Preclinical Data on ART26.12 in Breast Cancer-Induced Bone Pain at the 34th Annual International Cannabinoid Research Society Symposium - Quantisnow
Artelo Biosciences Inc Stock (ARTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):